USD10
VRTX Shares
About Vertex PharmaceuticalsVertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
USD10
VRTX Shares
About Vertex PharmaceuticalsVertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Stats
TRADING WINDOW
Open
CLOSES AT
8:00 PM GMT+0
MARKET CAP
$114.72B
OPEN PRICE
$447.02
LOW (1Y)
$362.50
HIGH (1Y)
$512.71
LOW (24H)
$441.20
HIGH (24H)
$452.08
VOLUME (24H)
$587.17K
54.69%
Price history
Time | Price | Change |
|---|---|---|
Today | $447.02 | |
1 Day | $452.50 | |
1 Week | $462.48 | |
1 Month | $488.81 | |
1 Year | $509.04 |